These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 39237765)
61. PPM1D suppresses p53-dependent transactivation and cell death by inhibiting the Integrated Stress Response. Andrysik Z; Sullivan KD; Kieft JS; Espinosa JM Nat Commun; 2022 Dec; 13(1):7400. PubMed ID: 36456590 [TBL] [Abstract][Full Text] [Related]
62. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Astle MV; Hannan KM; Ng PY; Lee RS; George AJ; Hsu AK; Haupt Y; Hannan RD; Pearson RB Oncogene; 2012 Apr; 31(15):1949-62. PubMed ID: 21909130 [TBL] [Abstract][Full Text] [Related]
63. Identification of PPM1D as an essential Ulk1 phosphatase for genotoxic stress-induced autophagy. Torii S; Yoshida T; Arakawa S; Honda S; Nakanishi A; Shimizu S EMBO Rep; 2016 Nov; 17(11):1552-1564. PubMed ID: 27670885 [TBL] [Abstract][Full Text] [Related]
64. Mutation of the LXCXE binding cleft of pRb facilitates transformation by ras in vitro but does not promote tumorigenesis in vivo. Talluri S; Francis SM; Dick FA PLoS One; 2013; 8(8):e72236. PubMed ID: 23936539 [TBL] [Abstract][Full Text] [Related]
65. PPM1D regulates p21 expression via dephoshporylation at serine 123. Cao R; Zhang J; Zhang M; Chen X Cell Cycle; 2015; 14(4):641-7. PubMed ID: 25590690 [TBL] [Abstract][Full Text] [Related]
66. Expression and gene doses changes of the p53-regulator PPM1D in meningiomas: a role in meningioma progression? Fukami S; Riemenschneider MJ; Kohno M; Steiger HJ Brain Tumor Pathol; 2016 Jul; 33(3):191-9. PubMed ID: 26942600 [TBL] [Abstract][Full Text] [Related]
67. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib. Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503 [TBL] [Abstract][Full Text] [Related]
68. PPM1D silencing by lentiviral-mediated RNA interference inhibits proliferation and invasion of human glioma cells. Wang P; Rao J; Yang H; Zhao H; Yang L J Huazhong Univ Sci Technolog Med Sci; 2011 Feb; 31(1):94-99. PubMed ID: 21336731 [TBL] [Abstract][Full Text] [Related]
69. PPM1D in Solid and Hematologic Malignancies: Friend and Foe? Zhang L; Hsu JI; Goodell MA Mol Cancer Res; 2022 Sep; 20(9):1365-1378. PubMed ID: 35657598 [TBL] [Abstract][Full Text] [Related]
70. WIP1 phosphatase as a potential therapeutic target in neuroblastoma. Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463 [TBL] [Abstract][Full Text] [Related]
72. Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy. Kim B; Won D; Lee ST; Choi JR PLoS One; 2019; 14(6):e0217521. PubMed ID: 31242196 [TBL] [Abstract][Full Text] [Related]
73. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability. Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814 [TBL] [Abstract][Full Text] [Related]
74. 58-kDa microspherule protein (MSP58) is novel Brahma-related gene 1 (BRG1)-associated protein that modulates p53/p21 senescence pathway. Hsu CC; Lee YC; Yeh SH; Chen CH; Wu CC; Wang TY; Chen YN; Hung LY; Liu YW; Chen HK; Hsiao YT; Wang WS; Tsou JH; Tsou YH; Wu MH; Chang WC; Lin DY J Biol Chem; 2012 Jun; 287(27):22533-48. PubMed ID: 22563078 [TBL] [Abstract][Full Text] [Related]
75. The Wip1 Phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Lu X; Ma O; Nguyen TA; Jones SN; Oren M; Donehower LA Cancer Cell; 2007 Oct; 12(4):342-54. PubMed ID: 17936559 [TBL] [Abstract][Full Text] [Related]
76. The role of PPM1D in cancer and advances in studies of its inhibitors. Deng W; Li J; Dorrah K; Jimenez-Tapia D; Arriaga B; Hao Q; Cao W; Gao Z; Vadgama J; Wu Y Biomed Pharmacother; 2020 May; 125():109956. PubMed ID: 32006900 [TBL] [Abstract][Full Text] [Related]
77. Nutlin-3a, an MDM2 antagonist and p53 activator, helps to preserve the replicative potential of cancer cells treated with a genotoxic dose of resveratrol. Zajkowicz A; Krześniak M; Matuszczyk I; Głowala-Kosińska M; Butkiewicz D; Rusin M Mol Biol Rep; 2013 Aug; 40(8):5013-26. PubMed ID: 23666059 [TBL] [Abstract][Full Text] [Related]
78. Oncogenic properties of PPM1D located within a breast cancer amplification epicenter at 17q23. Li J; Yang Y; Peng Y; Austin RJ; van Eyndhoven WG; Nguyen KC; Gabriele T; McCurrach ME; Marks JR; Hoey T; Lowe SW; Powers S Nat Genet; 2002 Jun; 31(2):133-4. PubMed ID: 12021784 [TBL] [Abstract][Full Text] [Related]
79. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Sarkisian CJ; Keister BA; Stairs DB; Boxer RB; Moody SE; Chodosh LA Nat Cell Biol; 2007 May; 9(5):493-505. PubMed ID: 17450133 [TBL] [Abstract][Full Text] [Related]
80. PPM1D is a potential prognostic biomarker and correlates with immune cell infiltration in hepatocellular carcinoma. Yu Z; Song Y; Cai M; Jiang B; Zhang Z; Wang L; Jiang Y; Zou L; Liu X; Yu N; Mao X; Peng C; Liu S Aging (Albany NY); 2021 Sep; 13(17):21294-21308. PubMed ID: 34470916 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]